Navigation Links
InterMune to Present at Goldman Sachs Healthcare Conference
Date:6/3/2009

BRISBANE, Calif., June 3 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Daniel Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the Goldman Sachs 30th Annual Global Healthcare Conference in New York on June 9, 2009 at 2:35 p.m. ET.

To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF, RECAP, an open-label extension study from CAPACITY and a research program focused on small molecules for the treatment of pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche, its development partner) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating new targets in hepatology. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NIAGARA FALLS, N.Y., Jan. 15, 2014   Niagara ... has been selected by Buffalo BioBlower Technologies LLC ("B3") ... its SBIR Phase 2 award from the Army Corps ... purification system that kills all biological contaminants and destroys ...
(Date:1/15/2014)... England and SAN JOSE, California ... international biotechnology company developing antibody-drug conjugates for cancer, today announced ... Board of Directors. Dr Reynolds has over 20 years, development ... Medical Officer at Seattle Genetics. "I am delighted ...
(Date:1/15/2014)... January 15, 2014 A study has been ... the Formula 1 track could help to tackle the problem ... (MAT), Stowhealth (a GP surgery based in Stowmarket) and academics ... Simplyhealth. Telemetry technology, which is inspired by equipment ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 The Microcompetition with ... major disease. One of these latent viruses is the Epstein ... arthritis (RA). Rheumatoid arthritis (RA) is a chronic inflammatory disease ... a study found that RA patients have high concentrations of ...
Breaking Biology Technology:Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... The Science Advisory Board,( http://www.scienceboard.net ), a ... its ten-year anniversary -- making it one of,the ... Science Advisory Board is a division of BioInformatics, ... serving more than,300 clients in the biotechnology, pharmaceutical, ...
... EXTON, Pa., Sept. 12 Kensey Nash Corporation,(Nasdaq: ... Sixth Annual West Coast Emerging,Growth Institutional Investor Forum ... 2007. Joseph W. Kaufmann, Kensey Nash,s President ... approximately 7:55 a.m. (PT). The,presentation materials will be ...
... BNVI ), a pharmaceutical company focused on the discovery and,development ... health and,cancer, announced today that Tom Chesterman, SVP and CFO ... Growth Conference in New,York. The presentation is scheduled to ... the New York Palace Hotel in New York. A ...
Cached Biology Technology:Social Network for Scientists Marks Ten Years Online 2Social Network for Scientists Marks Ten Years Online 3Kensey Nash to Present at the Sidoti Sixth Annual West Coast Emerging Growth Institutional Investor Forum Conference 2Bionovo to Present at A.G. Edwards' 2nd Annual Emerging Growth Conference 2007 2
(Date:4/17/2014)... one per eight hundred births, Down syndrome - or ... of intellectual disability. It results from a chromosomal abnormality ... of chromosome 21 (1% of the human genome). A ... the Department of Genetic Medicine and Development at the ... Nature , shed light on how the extra ...
(Date:4/17/2014)... KAN. A Kansas State University engineer has ... and remotely detects improvised explosive devices. The same ... William Dunn, the Steven M. and Kay L. ... mechanical and nuclear engineering, and his research team ... hidden underground or in car trunks. The distance ...
(Date:4/17/2014)... One day about eight years ago, Katia ... Riverside, and her father were on a field trip in ... an orchid they had never seen before. , Unable to ... orchids. The orchid turned out to be an unnamed ... Lophiaris silverarum . , "Lophiaris" is the genus name, comprising ...
Breaking Biology News(10 mins):Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3Patented research remotely detects nitrogen-rich explosives 2Orchid named after UC Riverside researcher 2Orchid named after UC Riverside researcher 3
... of undergraduate students from Stevens Institute of Technology was ... by the International Society for Pharmaceutical Engineering (ISPE). ... students and was held last month at the ISPE ... poster, titled "Evaluation of a Posterior Criciate Ligament Tensioning ...
... is good for you, at least if you are a ... Oncology Center have shown that in healthy cells, a bundled ... storehouse, in its proper place. Understanding this cap,s influence on ... to the diagnosis and treatment of diseases such as cancer, ...
... identification of substances involved in the Jekyll-and-Hyde transformation that ... bleaching." Their study appears in ACS, Environmental Science ... and colleagues note that bleaching already has destroyed up ... scientists are searching for ways to slow or stop ...
Cached Biology News:A cell's 'cap' of bundled fibers could yield clues to disease 2
96 Well Base Plate...
... recombinant protein that has been shown to help ... of cDNA by reverse transcription, in vitro RNA ... Safe Inhibitor tightly binds RNases in a 1:1 ... RNases such as RNase A, RNase B, RNase ...
... Kit contains all the necessary ... on a wide range of ... dNTPs, the Core Kit is ... BIOLASE DNA polymerase, which achieves ...
Chicken Aortic Smooth Muscle Cells (CAOSMC) (>500,000 cells)...
Biology Products: